Nishwant Swami1,2, Yefri A Baez3,4, Idalid Franco4,5,6, Tiffany Nguyen7, Karthik Meiyappan7, Minh Ton7, Bhav Jain8, Crystal Seldon9, Kenrick Ng10,11, Narjust Duma12, Mohammed Alshalalfa7, Kosj Yamoah13, Paul L Nguyen4,14, Brandon A Mahal15, Edward Christopher Dee16. 1. University of Massachusetts Medical School, Worcester, MA, USA. 2. Harvard T.H. Chan School of Public Health, Boston, MA, USA. 3. Department of Urology, Brigham and Women's Hospital, Boston, MA, USA. 4. Harvard Medical School, Boston, MA, USA. 5. Department of Radiation Oncology, Dana Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA, USA. 6. Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA. 7. University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center, Miami, Fl, USA. 8. Massachusetts Institute of Technology, Cambridge, MA, UK. 9. Department of Radiation Oncology, University of Miami/Jackson Memorial Hospital, Miami, USA. 10. Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, UK. 11. UCL Cancer Institute, University College London, London, UK. 12. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. 13. Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa, Fl, USA. 14. Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA, USA. 15. Department of Radiation Oncology, University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center, Miami, Fl, USA. bmahal@med.miami.edu. 16. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. deee1@mskcc.org.
Abstract
BACKGROUND: Despite great heterogeneity amongst Hispanic groups, prostate cancer studies often report Hispanic patients in aggregate. We sought to identify differences in prostate cancer risk group at presentation and treatment status among Hispanic subgroup populations. METHODS: Patients with localized prostate adenocarcinoma diagnosed from 2004-2017 were identified in the National Cancer Database (NCDB) and disaggregated by racial subgroup and Hispanic country of origin. Ordinal logistic regression defined adjusted odds ratios (AORs) with 95% CI of (1) presenting at progressively higher risk group and (2) receiving treatment with intermediate-unfavorable or high-risk disease. RESULTS: In our sample (n = 895,087), Hispanic men had greater odds of presenting with higher-risk localized prostate cancer compared with non-Hispanic White men (AOR = 1.18 95% CI 1.16-1.21, p < 0.001). Additionally, Hispanic Black men were less likely to present with higher-risk disease than non-Hispanic Black men. Disparities also existed when disaggregated by country of origin, particularly for Mexican men. Amongst men with unfavorable-risk disease, Hispanic men were less likely to receive treatment than non-Hispanic White men (95% CI 0.57-0.67, p < 0.001). The odds of Hispanic Black patients receiving treatment was 2.00 times the odds (95% CI 1.17-3.41 p = 0.011) of non-Hispanic Black patients receiving treatment. Upon disaggregation by country of origin, disparities persisted, particularly for Mexican men. CONCLUSION: We found marked heterogeneity when risk group at presentation and treatment for higher-risk disease were disaggregated by racial subgroup and country of origin. Our findings support further collection of disaggregated data in Hispanic communities and study of potential mechanisms underlying the observed differences.
BACKGROUND: Despite great heterogeneity amongst Hispanic groups, prostate cancer studies often report Hispanic patients in aggregate. We sought to identify differences in prostate cancer risk group at presentation and treatment status among Hispanic subgroup populations. METHODS: Patients with localized prostate adenocarcinoma diagnosed from 2004-2017 were identified in the National Cancer Database (NCDB) and disaggregated by racial subgroup and Hispanic country of origin. Ordinal logistic regression defined adjusted odds ratios (AORs) with 95% CI of (1) presenting at progressively higher risk group and (2) receiving treatment with intermediate-unfavorable or high-risk disease. RESULTS: In our sample (n = 895,087), Hispanic men had greater odds of presenting with higher-risk localized prostate cancer compared with non-Hispanic White men (AOR = 1.18 95% CI 1.16-1.21, p < 0.001). Additionally, Hispanic Black men were less likely to present with higher-risk disease than non-Hispanic Black men. Disparities also existed when disaggregated by country of origin, particularly for Mexican men. Amongst men with unfavorable-risk disease, Hispanic men were less likely to receive treatment than non-Hispanic White men (95% CI 0.57-0.67, p < 0.001). The odds of Hispanic Black patients receiving treatment was 2.00 times the odds (95% CI 1.17-3.41 p = 0.011) of non-Hispanic Black patients receiving treatment. Upon disaggregation by country of origin, disparities persisted, particularly for Mexican men. CONCLUSION: We found marked heterogeneity when risk group at presentation and treatment for higher-risk disease were disaggregated by racial subgroup and country of origin. Our findings support further collection of disaggregated data in Hispanic communities and study of potential mechanisms underlying the observed differences.
Authors: Robin M Weinick; Elizabeth A Jacobs; Lisa Cacari Stone; Alexander N Ortega; Helen Burstin Journal: Med Care Date: 2004-04 Impact factor: 2.983
Authors: Paul Riviere; Elaine Luterstein; Abhishek Kumar; Lucas K Vitzthum; Rishi Deka; Reith R Sarkar; Alex K Bryant; Andrew Bruggeman; John P Einck; James D Murphy; María Elena Martínez; Brent S Rose Journal: Cancer Date: 2020-01-27 Impact factor: 6.860
Authors: Daniel J Lee; Zhiguo Zhao; Li-Ching Huang; Tatsuki Koyoma; Matthew J Resnick; David F Penson; Daniel A Barocas; Karen E Hoffman Journal: Cancer Causes Control Date: 2018-08-11 Impact factor: 2.506
Authors: Robert T Dess; Holly E Hartman; Brandon A Mahal; Payal D Soni; William C Jackson; Matthew R Cooperberg; Christopher L Amling; William J Aronson; Christopher J Kane; Martha K Terris; Zachary S Zumsteg; Santino Butler; Joseph R Osborne; Todd M Morgan; Rohit Mehra; Simpa S Salami; Amar U Kishan; Chenyang Wang; Edward M Schaeffer; Mack Roach; Thomas M Pisansky; William U Shipley; Stephen J Freedland; Howard M Sandler; Susan Halabi; Felix Y Feng; James J Dignam; Paul L Nguyen; Matthew J Schipper; Daniel E Spratt Journal: JAMA Oncol Date: 2019-07-01 Impact factor: 31.777
Authors: S Jane Henley; Elizabeth M Ward; Susan Scott; Jiemin Ma; Robert N Anderson; Albert U Firth; Cheryll C Thomas; Farhad Islami; Hannah K Weir; Denise Riedel Lewis; Recinda L Sherman; Manxia Wu; Vicki B Benard; Lisa C Richardson; Ahmedin Jemal; Kathleen Cronin; Betsy A Kohler Journal: Cancer Date: 2020-03-12 Impact factor: 6.921
Authors: Edward Christopher Dee; Melaku A Arega; David D Yang; Santino S Butler; Brandon A Mahal; Nina N Sanford; Paul L Nguyen; Vinayak Muralidhar Journal: JCO Oncol Pract Date: 2021-02-25
Authors: Brandon A Mahal; Mohammed Alshalalfa; Kevin H Kensler; Ilkania Chowdhury-Paulino; Philip Kantoff; Lorelei A Mucci; Edward M Schaeffer; Daniel Spratt; Kosj Yamoah; Paul L Nguyen; Timothy R Rebbeck Journal: N Engl J Med Date: 2020-09-10 Impact factor: 176.079